Connecting you to content on EBSCOhost

Works by Ottesen, Lone H.

Results: 4

1

Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 3, p. 193, doi. 10.1007/s00280-023-04554-3

By:

Någård, Mats;
Ah-See, Mei-Lin;
Strauss, James;
Wise-Draper, Trisha;
Safran, Howard P.;
Nadeau, Laura;
Edenfield, William J.;
Lewis, Lionel D.;
Ottesen, Lone H.;
Li, Yan;
Mugundu, Ganesh M.

Publication type:

Article

2

Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.

Published in:

Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 2, p. 141, doi. 10.1007/s00280-023-04555-2

By:

Någård, Mats;
Ah-See, Mei-Lin;
Strauss, James;
Wise-Draper, Trisha;
Safran, Howard P.;
Nadeau, Laura;
Edenfield, William J.;
Lewis, Lionel D.;
Rekić, Dinko;
Dota, Corina;
Ottesen, Lone H.;
Li, Yan;
Mugundu, Ganesh M.

Publication type:

Article

3

A Comprehensive Methodology to Systematically Identify Drug Hypersensitivity and Anaphylactic Reactions in Clinical Trial Databases.

Published in:

Pharmaceutical Medicine, 2020, v. 34, n. 5, p. 335, doi. 10.1007/s40290-020-00350-z

By:

Xavier, Hugo;
Hara, Indira;
Ottesen, Lone H.;
Verheijen, Remy B.;
Ghiorghiu, Dana;
Morgan, Claire

Publication type:

Article

4

Population pharmacokinetics modeling and analysis of foretinib in adult patients with advanced solid tumors.

Published in:

Journal of Clinical Pharmacology, 2015, v. 55, n. 10, p. 1184, doi. 10.1002/jcph.546

By:

Singh, Rajendra P.;
Patel, Bela;
Kallender, Howard;
Ottesen, Lone H.;
Adams, Laurel M.;
Cox, Donna S.

Publication type:

Article